Patients with low-grade glioma have no significant difference in progression-free survival when treated with either radiotherapy alone or temozolomide chemotherapy alone, according to a study published in The Lancet Oncology.1

Researchers in the Netherlands conducted a randomized, open-label, phase 3 intergroup study of 477 patients to compare progression-free survival outcomes from the 2 single-modality treatment options.

Treatment allocation was randomly conducted online through a minimization technique with prospective stratification across 78 clinical centers by 1p deletion, contrast enhancement, age, and WHO performance status. Planned analysis was performed after 216 progression events.

Continue Reading

Median follow-up was 48 months. Median progression-free survival was 39 months for patients treated with temozolomide, and 46 months for those treated with radiotherapy.

Three recently defined molecular low-grade glioma subgroups–IDHmt, with or without 1p/19q co-deletion, or IDH wild type–were confirmed upon exploratory analyses in 318 molecularly-defined patients. Patients with IDHmt/non-codel tumors who were treated with radiotherapy had longer progression-free survival than patients treated with temozolomide.

RELATED: For Patients With Malignant Glioma, Optimism and Prognostic Awareness Not Mutually Exclusive

Thirty-two of the 236 patients treated with temozolomide experienced grade 3 to 4 hematological adverse events, in contrast with 1 of 228 patients treated with radiotherapy. Eight of the patients treated with temozolomide experienced grade 3 to 4 infections, in contrast with 2 treated with radiotherapy.


  1. Baumert BG, Hegi ME, van den Bent MJ, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. The Lancet Oncol. 2016 Sep 27. doi: 10.1016/S1470-2045(16)30313-8 [Epub ahead of print]